Loviride is an experimental antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s, but failed to gain marketing approval because of poor potency.[1] It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR[2] and AVANTI[3]), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to the NNRTIs efavirenz and nevirapine.
↑"Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial". The Lancet349 (9063): 1413–1421. 1997. doi:10.1016/S0140-6736(97)04441-3. https://dare.uva.nl/personal/pure/en/publications/randomised-trial-of-addition-of-lamivudine-or-lamivudine-plus-loviride-to-zidovudinecontaining-regimens-for-patients-with-hiv1-infection-the-caesar-trial(60592251-8bcd-4787-8c25-b7115864937b).html.
↑"AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group". Antiviral Therapy4 (2): 79–86. 1999. doi:10.1177/135965359900400204. PMID 10682152.
v
t
e
Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Entry/fusion inhibitors (Discovery and development)
From Handwiki 
(what is this?) (verify)
KSF